PTC Therapeutics Option Alert: Jun 20 $40 Puts at the Bid: 2121 vs 2889 OI; Earnings 5/6 After Close 

PTC Therapeutics Option Alert: Jun 20 $40 Puts at the Bid: 2121 @ $3.0 vs 2889 OI; Earnings 5/6 After Close Ref=$39.23

PTC Therapeutics (NASDAQ:PTCT) 주식

PTC THERAPEUTICS INC

PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) price target from $115 to $125. Needham analyst Mike Cikos maintained a Buy rating. Okta shares closed at $125.50 on Tuesday. See how other<a href="https://www.benzinga.com/quote/OKTA/analyst-ratings"> analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) from $180 to $195. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Franco-Nevada shares closed at $168.24 on Tuesday. <a href="https://www.benzinga.com/quote/FNV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies cut Rocket Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) price target from $29 to $2.5. Jefferies analyst Andrew Tsai downgraded the stock from Buy to Hold. Rocket Pharmaceuticals shares closed at $2.33 on Tuesday. <a href="https://www.benzinga.com/quote/RCKT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo increased the price target for Barings BDC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBDC#NYSE">BBDC</a>) from $8.5 to $9.5. Wells Fargo analyst Finian O&#8217;Shea upgraded the stock from Equal-Weight to Overweight. Barings BDC shares closed at $9.24 on Tuesday. <a href="https://www.benzinga.com/quote/bbdc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Runway Growth Finance Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RWAY#NASDAQ">RWAY</a>) from $10 to $9.5. Wells Fargo analyst Finian O&#8217;Shea downgraded the stock from Overweight to Equal-Weight. Runway Growth Finance shares closed at $9.83 on Tuesday. See how <a href="https://www.benzinga.com/quote/RWAY/analyst-ratings">other analysts view this stock</a>.</li>
<li>D. Boral Capital cut CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) price target from $14 to $12. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. CollPlant Biotechnologies shares settled at $1.93 on Tuesday. <a href="https://www.benzinga.com/quote/CLGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Bridger Aerospace Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) price target from $5 to $5.25. Canaccord Genuity analyst Austin Moeller maintained a Buy rating. Bridger Aerospace shares closed at $1.37 on Tuesday. <a href="https://www.benzinga.com/quote/BAER/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) price target from $400 to $350. Canaccord Genuity analyst David Hynes maintained a Buy rating. Salesforce shares closed at $277.19 on Tuesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from $7 to $6. Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating. Sunrun shares settled at $7.19 on Tuesday. <a href="https://www.benzinga.com/quote/RUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised The Williams Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) price target from $64 to $67. Wells Fargo analyst Praneeth Satish maintained an Overweight rating. Williams Companies shares closed at $60.10 on Tuesday. <a href="https://www.benzinga.com/quote/WMB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying OKTA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-1024x585.png" alt="" class="wp-image-929866" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/28084823/image-360.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45616471/jim-cramer-says-rocket-is-a-very-fine-company-recommends-buying-this-health-care-stock">Jim Cramer Says Rocket Is A &#8216;Very Fine&#8217; Company, Recommends Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

News

Price Target

Markets

Analyst Ratings

Trading Ideas

BAER

BBDC

CLGN

OKTA

PRTA

PTCT

RCKT

RWAY

Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Ascendiant Capital raised Pro-Dex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) price target from $54 to $56. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Pro-Dex shares closed at $46.24 on Friday. <a href="https://www.benzinga.com/quote/PDEX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Unity Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) from $4 to $2. HC Wainwright &amp; Co. analyst Matthew Caufield downgraded the stock from Buy to Neutral. Unity Biotechnology shares closed at $0.7790 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/UBX/analyst-ratings">view this stock</a>.</li>
<li>JMP Securities cut Churchill Downs Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) price target from $144 to $138. JMP Securities analyst Jordan Bender maintained a Market Outperform rating. Churchill Downs shares closed at $93.24 on Friday. See how other <a href="https://www.benzinga.com/quote/CHDN/analyst-ratings">analysts view this stock</a>.</li>
<li>JMP Securities increased the price target for DBV Technologies S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) from $15 to $21. JMP Securities analyst Jonathan Wolleben maintained a Market Outperform rating. DBV Technologies shares closed at $8.41 on Friday. <a href="https://www.benzinga.com/quote/DBVT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased the price target for Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from $85 to $100. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar General shares closed at $101.39 on Friday. See how other <a href="https://www.benzinga.com/quote/DG/analyst-ratings">analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) price target from $30 to $14. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $82 to $95. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $88.17 on Friday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim cut Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) price target from $155 to $115. Guggenheim analyst Robert Drbul maintained a Buy rating. Target shares closed at $94.29 on Friday.  <a href="https://www.benzinga.com/quote/TGT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital cut the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $40 to $18. Chardan Capital analyst Rudy Li maintained a Buy rating. Prothena shares settled at $6.58 on Friday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $68 to $74. Wells Fargo analyst Tiago Fauth maintained an Overweight rating. PTC Therapeutics shares closed at $45.93 on Friday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PTCT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png" alt="" class="wp-image-928475" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27100119/image-340.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45585696/how-to-earn-500-a-month-from-dicks-sporting-goods-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dick&#8217;s Sporting Goods Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

CHDN

DBVT

DLTR

PDEX

PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday

Wells Fargo analyst Tiago Fauth maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and raises the price target from $68 to $74.

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $74

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Tycho Peterson upgraded the rating for GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) from Hold to Buy and announced a target of $80. GeneDx shares closed at $56.36 on Thursday. <a href="https://www.benzinga.com/quote/wgs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Paul Lejuez upgraded the rating for National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) from Neutral to Buy and raised the price target from $13 to $21. National Vision shares closed at $16.68 on Thursday. <a href="https://www.benzinga.com/quote/eye/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad upgraded PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Neutral to Buy and raised the price target from $55 to $68. PTC Therapeutics shares closed at $42.51 on Thursday. <a href="https://www.benzinga.com/quote/ptct/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying EYE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="614" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-1024x614.png" alt="" class="wp-image-910039" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-1024x614.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-768x460.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

CVRX

WOLF

This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

B of A Securities analyst Tazeen Ahmad upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Neutral to Buy and raises the price target from $55 to $68.

B of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68

Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and lowers the price target from $56 to $42.

Barclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $42

Baird analyst Joel Beatty maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and lowers the price target from $70 to $66.

Baird Maintains Outperform on PTC Therapeutics, Lowers Price Target to $66

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and raises the price target from $57 to $58.

RBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $58

WIIM

PTC Therapeutics shares are trading higher after the company reported Q1 financial results and raised its FY25 sales guidance. Also, Citigroup upgraded its price target on the stock from Sell to Neutral.

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $113 to $112.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $112

JP Morgan analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $75 to $67.

JP Morgan Maintains Overweight on PTC Therapeutics, Lowers Price Target to $67

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised BlackLine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) price target from $46 to $50. Piper Sandler analyst Brent Bracelin maintained a Neutral rating. BlackLine shares closed at $46.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/BL/analyst-ratings">analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed the price target for Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) from $10 to $7. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating. Under Armour shares closed at $5.70 on Tuesday. <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital cut CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) price target from $84 to $82. Chardan Capital analyst Geulah Livshits maintained a Buy rating. CRISPR Therapeutics shares closed at $33.16 on Tuesday. <a href="https://www.benzinga.com/quote/CRSP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity slashed the price target for Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from $150 to $145. Canaccord Genuity analyst Kingsley Crane maintained a Buy rating. Datadog shares closed at $106.06 on Tuesday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners raised the price target for Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from $4 to $10. Leerink Partners analyst Marc Goodman upgraded the stock from Market Perform to Outperform. Amylyx Pharmaceuticals shares closed at $4.65 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/AMLX/analyst-ratings">this stock</a>.</li>
<li>Citigroup cut PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $50 to $40. Citigroup analyst Geoff Meacham upgraded the stock from Sell to Neutral. PTC Therapeutics shares settled at $36.19 on Tuesday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) price target from $85 to $94. Rosenblatt analyst Mike Genovese maintained a Buy rating. Lumentum shares closed at $64.42 on Tuesday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) price target from $145 to $130. Needham analyst Ryan Koontz maintained a Buy rating. Arista Networks shares closed at $90.77 on Tuesday.  <a href="https://www.benzinga.com/quote/ANET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research raised the price target for Grand Canyon Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) from $205 to $215. Barrington Research analyst Alexander Paris maintained an Outperform rating. Grand Canyon Education shares settled at $185.45 on Tuesday. <a href="https://www.benzinga.com/quote/LOPE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity cut Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) price target from $163 to $158. Canaccord Genuity analyst Michael Walkley maintained a Buy rating. Qualys shares closed at $126.82 on Tuesday. <a href="https://www.benzinga.com/quote/QLYS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LITE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-1024x585.png" alt="" class="wp-image-905454" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ANET

CRSP

DDOG

LITE

LOPE

QLYS

Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Leerink Partners analyst Marc Goodman upgraded the rating for Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from Market Perform to Outperform and raised the price target from $4 to $10. Amylyx Pharmaceuticals shares closed at $4.65 on Tuesday. <a href="https://www.benzinga.com/quote/amlx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham upgraded PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Sell to Neutral but lowered the price target from $50 to $40. PTC Therapeutics shares closed at $36.19 on Tuesday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joern Iffert upgraded the rating for Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) from Neutral to Buy. Logitech International shares closed at $76.52 on Tuesday. <a href="https://www.benzinga.com/quote/LOGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research analyst James Goss upgraded CuriosityStream Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) from Market Perform to Outperform and announced a $6 price target. CuriosityStream shares closed at $3.30 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LOGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-1024x627.png" alt="" class="wp-image-905410" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-1024x627.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-768x470.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

CURI

LOGI

RDDT

This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Citigroup analyst Geoff Meacham upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Sell to Neutral and lowers the price target from $50 to $40.

Citigroup Upgrades PTC Therapeutics to Neutral, Lowers Price Target to $40

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) raises FY2025 sales outlook from $600.00 million-$800.00 million to $650.00 million-$800.00 million vs $720.13 million estimate.

Guidance

PTC Therapeutics Raises FY2025 Sales Guidance from $600.00M-$800.00M to $650.00M-$800.00M vs $720.13M Est

Earnings

Earnings Beats

PTC Therapeutics Q1 EPS $10.04, Sales $1.18B

<a href="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics" title="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics">https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics</a>

Biotech

General

BHVN

CAPR

DSGN

MRNA

NVAX

SLDB

SRPT

TSHA

XNCR

'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CVGI

CXDO

CYTK

DASH

DAWN

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Huntington&#8217;s disease (HD) patients</a>.
Huntington&#8217;s disease is&nbsp;a progressive neurodegenerative disorder caused by mutation of the&nbsp;huntingtin&nbsp;(HTT) gene, leading to the breakdown of brain cells.&nbsp;It is characterized by uncontrolled movements (chorea), cognitive decline, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45190339/ptc518-pivot-hd-study-achieves-primary-endpoint" rel="noreferrer noopener">and psychiatric disturbances</a>.
The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p&lt;0.0001) at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44538151/european-commission-declines-to-renew-marketing-authorization-of-translarna-duchenne-muscular-disorder" rel="noreferrer noopener">European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder</a>
&#8220;We look forward to discussions on the next development and regulatory steps, including the potential for accelerated approval as we work to potentially bring the first disease-modifying therapy&#8230;,&#8221; said&nbsp;Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
Results from the full 12-month cohort demonstrate dose-dependent lowering in blood HTT levels, with 23% at the 5mg dose level for both Stage 2 and 3 patients and 39% and 36% at the 10mg dose level for Stage 2 and 3 patients, respectively. For Stage 2 patients, there were dose-dependent trends of benefit on clinical scales, including the Composite Unified Huntington&#8217;s Disease Rating Scale (cUHDRS) and Total Motor Score (TMS) subscale.
For Stage 3 patients, trends favored the 5mg dose group relative to placebo but not the 10mg dose group, suggesting that treatment effect may differ in Stage 3 patients relative to Stage 2 patients. It seems investors are reacting to this as the stock is trading almost 20% lower during the premarket session.
PTC518 showed a favorable safety and tolerability profile for all dose levels and disease stages with no treatment-related serious adverse events or neurofilament light chain protein&nbsp;(NfL) spikes.
In addition, 24-month treatment data from the patients on whom data were shared last year (N=21) demonstrate signals of dose-dependent trends on the cUHDRS, Total Function Capacity (TFC), and Symbol Digit Modalities Test (SDMT) subscales when compared to a propensity-matched natural history cohort from the ENROLL-HD Registry.
At Month 24, there was also a dose-dependent lowering of plasma NfL from a baseline of -8.9% (nominal p=0.12) for the 5mg dose level and -14% (nominal p=0.03) for the 10mg dose level.
In April, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the marketing authorization application for Sephience (sepiapterin) for phenylketonuria (PKU). The opinion includes a broad label that includes <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45007096/ptc-therapeutics-receives-positive-chmp-opinion-for-sephience-sepiapterin-for-the-treatment-of-chi" rel="noreferrer noopener">all ages and disease severities</a>.
Price Action: PTCT stock fell 18.60% to $40.65&nbsp;on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a></li>
</ul>

Health Care

Movers

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 52.8% to $0.7 during Monday's regular session. The company's market cap stands at $4.2 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock moved upwards by 35.6% to $2.32. The market value of their outstanding shares is at $337.2 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock moved upwards by 33.33% to $2.4. The company's market cap stands at $11.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 31.91% to $80.8. The company's market cap stands at $1.0 billion. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares rose 23.54% to $4.25. The company's market cap stands at $62.9 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 23.2% to $0.31. The market value of their outstanding shares is at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock decreased by 26.4% to $12.4 during Monday's regular session. The company's market cap stands at $957.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 23.47% to $1.37. The market value of their outstanding shares is at $18.2 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 22.46% to $0.58. The market value of their outstanding shares is at $6.6 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 21.2% to $2.38. The market value of their outstanding shares is at $139.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 19.49% to $2.04. The market value of their outstanding shares is at $1.8 billion. </li>
<li>PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) stock declined by 17.48% to $41.22. The market value of their outstanding shares is at $3.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CYCC

IART

IBRX

IMMP

NCNA

12 Health Care Stocks Moving In Monday's Intraday Session

Press Releases

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Comments

PTC Therapeutics

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌